These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34024035)

  • 1. Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler
    Bartels C; Jain M; Yu J; Tillmann HC; Vaidya S
    Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):487-504. PubMed ID: 34024035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects.
    Inoue S; Vaidya S; Tillmann HC; Sakita Y; Machineni S; Heudi O; Furihata K
    BMC Pulm Med; 2021 Jan; 21(1):18. PubMed ID: 33413291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
    Kerstjens HAM; Maspero J; Chapman KR; van Zyl-Smit RN; Hosoe M; Tanase AM; Lavecchia C; Pethe A; Shu X; D'Andrea P;
    Lancet Respir Med; 2020 Oct; 8(10):1000-1012. PubMed ID: 32653074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials.
    Scosyrev E; van Zyl-Smit R; Kerstjens H; Gessner C; Kornmann O; Jain D; Aubrun E; D'Andrea P; Hosoe M; Pethe A; Brittain D
    Respir Med; 2021; 180():106311. PubMed ID: 33711782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON).
    Gessner C; Kornmann O; Maspero J; van Zyl-Smit R; Krüll M; Salina A; Gupta P; Bostel S; Fucile S; Conde LG; Pfister P
    Respir Med; 2020; 170():106021. PubMed ID: 32843164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma.
    Brittain D; D'Andrea P; Gruen E; Hosoe M; Jain D; Jauernig J; Pethe A; Scosyrev E; Tanase AM; Tillmann HC
    Adv Ther; 2022 Jun; 39(6):2365-2378. PubMed ID: 35072888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects.
    Vaidya S; Jauernig J; Ethell B; Abdallah N; Machineni S; Drollmann A; Heudi O; Last S; Hahn M; Radhakrishnan R; Ignatenko S; Tillmann HC
    Pulm Pharmacol Ther; 2020 Oct; 64():101964. PubMed ID: 33035700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study.
    van Zyl-Smit RN; Krüll M; Gessner C; Gon Y; Noga O; Richard A; de Los Reyes A; Shu X; Pethe A; Tanase AM; D'Andrea P;
    Lancet Respir Med; 2020 Oct; 8(10):987-999. PubMed ID: 32653075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study.
    Watz H; Hohlfeld JM; Singh D; Beier J; Diamant Z; Liu J; Hua S; Abd-Elaziz K; Pinot P; Jones I; Tillmann HC
    Respir Res; 2020 Apr; 21(1):87. PubMed ID: 32295593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects
.
    Ren S; Sechaud R; Su Z; Tillmann HC; Hara H; Tan X; Hou J; Woessner R; Zhao R
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):147-155. PubMed ID: 27841152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/ indacaterol/glycopyrronium in patients with asthma.
    Buhl R; Nikolaev I; Tillmann HC; Vaidya S; Bartels C; Jain M; Jauernig J; Kerstjens HAM
    Pulm Pharmacol Ther; 2021 Oct; 70():102068. PubMed ID: 34329722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Utility Analysis of Fixed-Dose Combination of Indacaterol Acetate Glycopyrronium Bromide and Mometasone Furoate as a Maintenance Treatment in Adult Patients with Asthma Not Adequately Controlled with a Maintenance Combination of a Long-Acting Beta-Agonist and a High Dose of an Inhaled Corticosteroid Who Experienced One or More Asthma Exacerbations in the Previous Year.
    Mangia PP; Gallo O; Ritrovato D; Pradelli L
    Clin Drug Investig; 2021 Sep; 41(9):785-794. PubMed ID: 34333742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients.
    Demin I; Bartels C; Graham G; Bieth B; Gautier A; Tillmann HC; Sechaud R
    Int J Clin Pharmacol Ther; 2016 Jun; 54(6):405-15. PubMed ID: 27049057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population.
    Sagara H; Barbier N; Ishii T; Yoshisue H; Nikolaev I; Hosoe M; Gon Y
    BMJ Open Respir Res; 2021 Mar; 8(1):. PubMed ID: 33737310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study.
    Van Zyl-Smit RN; Kerstjens HA; Maspero JF; Kostikas K; Hosoe M; Tanase AM; D'Andrea P; Mezzi K; Brittain D; Lawrence D; Chapman KR
    Respir Med; 2023 May; 211():107172. PubMed ID: 36906187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects.
    Vaidya SS; Khindri S; Calder N; Machineni S; Hara H; Majumdar T; Febbraro S; Fuhr R; Woessner R
    Pulm Pharmacol Ther; 2016 Apr; 37():30-6. PubMed ID: 26845343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings.
    Kornmann O; Mucsi J; Kolosa N; Bandelli L; Sen B; Satlin LC; D'Andrea P
    Respir Med; 2020 Jan; 161():105809. PubMed ID: 32056721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
    Vincken W; Aumann J; Chen H; Henley M; McBryan D; Goyal P
    Int J Chron Obstruct Pulmon Dis; 2014; 9():215-28. PubMed ID: 24596459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate high-dose, and indacaterol acetate/mometasone furoate high-dose, in Japanese patients with inadequately controlled asthma: Results from two open-label, 52-week studies.
    Sagara H; D'Andrea P; Tanase AM; Pethe A; Tanaka Y; Matsuo K; Hosoe M; Nakamura Y
    J Asthma; 2023 Feb; 60(2):403-411. PubMed ID: 35348408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
    Dahl R; Jadayel D; Alagappan VK; Chen H; Banerji D
    Int J Chron Obstruct Pulmon Dis; 2013; 8():501-8. PubMed ID: 24159259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.